Biosimilar Clinical Development: Scientific Considerations and New Methodologies
Chapman & Hall/CRC (Verlag)
978-0-367-73652-1 (ISBN)
- Titel z.Zt. nicht lieferbar
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
Dr. Kerry B. Barker is the Vice-President and Head of Early Oncology Research Statistics at Pfizer, Dr. Sandeep Menon is the Vice-President and Head of Biostatistics Research and Consulting Center at Pfizer , Dr. Ralph D’Agostino is a professor of Mathematics and Statistics at Boston University, Dr. Siyan Xu is a senior principal biostatistician at Novartis and Dr.Bo Jin is the Director of Biostatistics in Early Oncology Research at Pfizer. All have been involved with biosimilars clinical development across all regions of the world.
Biosimilars for Drug Development. Regulatory Requirements on Biosimilars. System Biology in the Context of Biosimilars. Clinical Considerations on Biosimilars. Large Molecules Complete Molecular Confidence (CMC) Development Strategy. Immunogenicity. Interchangeability. Bridging a New Biologic to Its Reference Biologic. How to Account Covariate Effect to Show Non-Inferiority in Biosimilars. Novel Method in Inference of Equivalence in Biosimilars. Multiplicity Adjustment in Equivalence Using Two One-Sided Tests. Bayesian Methods in Biosimilar Studies.
Erscheinungsdatum | 16.01.2021 |
---|---|
Reihe/Serie | Chapman & Hall/CRC Biostatistics Series |
Sprache | englisch |
Maße | 156 x 234 mm |
Gewicht | 500 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
Studium ► Querschnittsbereiche ► Epidemiologie / Med. Biometrie | |
Naturwissenschaften ► Biologie | |
Sozialwissenschaften ► Soziologie | |
ISBN-10 | 0-367-73652-7 / 0367736527 |
ISBN-13 | 978-0-367-73652-1 / 9780367736521 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich